Literature DB >> 25702057

Treatment of dyslipidemia in HIV.

Rajagopal V Sekhar1.   

Abstract

Patients infected with HIV have a high risk of developing dyslipidemia. Effective therapeutic strategies can be challenging due to an increase risk of drug interactions and other comorbidities. Understanding the underlying pathophysiology and the principles of pharmacological and non-pharmacological therapeutic interventions can be of value in the appropriate management of dyslipidemia in the HIV-infected patient.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25702057     DOI： 10.1007/s11883-015-0493-x

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  81 in total

1.  Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.

Authors:  Jennifer H Lee; Jean L Chan; Epaminondas Sourlas; Vassilios Raptopoulos; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2006-04-24       Impact factor: 5.958

2.  Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy.

Authors:  Rosario Palacios; Jesús Santos; Mercedes González; Josefa Ruiz; Pedro Valdivielso; Manuel Márquez; Pedro González-Santos
Journal:  J Acquir Immune Defic Syndr       Date:  2002-08-15       Impact factor: 3.731

3.  Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.

Authors:  K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan
Journal:  J Acquir Immune Defic Syndr       Date:  2000-01-01       Impact factor: 3.731

4.  Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.

Authors:  Claude Gagné; Harold E Bays; Stuart R Weiss; Pedro Mata; Katherine Quinto; Michael Melino; Meehyung Cho; Thomas A Musliner; Barry Gumbiner
Journal:  Am J Cardiol       Date:  2002-11-15       Impact factor: 2.778

5.  Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome.

Authors:  Rajagopal V Sekhar; Farook Jahoor; Dinakar Iyer; Anuradha Guthikonda; Jaya Paranilam; Fareed Elhaj; Ivonne Coraza; Ashok Balasubramanyam
Journal:  Metabolism       Date:  2012-04-28       Impact factor: 8.694

6.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

Authors:  C Grunfeld; M Pang; W Doerrler; J K Shigenaga; P Jensen; K R Feingold
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

Review 7.  Use of diet, nutritional supplements and exercise in HIV-infected patients receiving combination antiretroviral therapies: a systematic review.

Authors:  Pere Leyes; Esteban Martínez; Maria de Talló Forga
Journal:  Antivir Ther       Date:  2008

8.  Relationship of peak growth hormone to cardiovascular parameters, waist circumference, lipids and glucose in HIV-infected patients and healthy adults.

Authors:  Janet Lo; Sung M You; Jeffrey Wei; Bridget Canavan; Steven Grinspoon
Journal:  Clin Endocrinol (Oxf)       Date:  2009-04-17       Impact factor: 3.478

9.  HIV infection and high density lipoprotein metabolism.

Authors:  Honor Rose; Jennifer Hoy; Ian Woolley; Urbain Tchoua; Michael Bukrinsky; Anthony Dart; Dmitri Sviridov
Journal:  Atherosclerosis       Date:  2007-12-04       Impact factor: 5.162

10.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Authors:  Signe Westring Worm; Caroline Sabin; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Eric Fontas; Ian Weller; Andrew Phillips; Jens Lundgren
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226
View more
  4 in total

1.  Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy.

Authors:  Daisuke Mizushima; Nguyen Thi Hoai Dung; Nguyen Thi Dung; Shoko Matsumoto; Junko Tanuma; Hiroyuki Gatanaga; Nguyen Vu Trung; Nguyen Van Kinh; Shinichi Oka
Journal:  Glob Health Med       Date:  2020-02-29

2.  ω-3 supplementation in HIV-1-infected individuals with unsuppressed viral load: cause for caution?

Authors:  Olivia Tort; Sonsoles Sánchez-Palomino; Tuixent Escribà; Carlos Calvo; Tània González; José Maria Gatell; Aleix Sala-Vila; Mireia Arnedo
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

Review 3.  HIV: how to manage dyslipidaemia in HIV.

Authors:  Daniel Lee
Journal:  Drugs Context       Date:  2022-03-01

Review 4.  Evidence-based review of statin use in patients with HIV on antiretroviral therapy.

Authors:  Daniel B Chastain; Kayla R Stover; Daniel M Riche
Journal:  J Clin Transl Endocrinol       Date:  2017-02-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.